SIBN earnings / call / takeaways

SIBN Q3 FY26 earnings call: key takeaways

What SIBN said on its earnings call of November 2, 2026: results against expectations, what changed since last quarter, guidance and the questions analysts pressed on.

By Lician·November 2, 2026·AI-generated from the call transcript and Lician data

EPS of -$0.08 beat the -$0.13 consensus (5:09)
Revenue of $56 million exceeded the $55.31 million consensus (3:44)
The company raised full-year revenue guidance. (19:12)

Results vs expectations

Metric	Consensus	Reported	Result
EPS	-$0.13	-$0.08	beat
Revenue	$55.3M	–	–

EPS basis: GAAP diluted EPS, SEC 10-Q

The stock moved +17.6% over the report window (S&P 500 ETF +0.3%). Earnings history

What changed since last quarter

Raised full-year revenue guidance to $231 million to $230 million from $230 million to $233 million. (19:12)
Maintained full-year gross margin guidance at 79% despite strong first-half performance. (19:12)
Increased R&D investment in the second half of 2026 to advance longer-term programs. (17:20)

Guidance

Metric	This call	Previous call
Revenue	$231 million to $230 million in worldwide revenue for 2026 (19:12)	not captured

What analysts pressed on

Whether the new product launch will face challenges in adoption. (24:22)
Concerns about the impact of reimbursement changes on procedure growth. (47:31)
Questions about the sustainability of revenue growth in the back half of the year. (22:30)

In their words

We believe the impact should be even more meaningful in 2027 as our new product moves through the adoption curve... (5:09)
We're pleased by the recent proposed CMS changes affecting SI joint fusion procedures. (8:26)
We have a track record of developing differentiated technologies, gaining reimbursement coverage, driving physician adoption... (5:09)
We're not just thinking about the stronger top line. We're thinking about the stronger top line. (58:04)

Read the full transcript with the AI summary, or listen on the company's official webcast.

Every past call in full and transcript search come with Lician Pro.

Written by AI from the automatic transcript of the company's public webcast and Lician's earnings data. Each sentence cites the passage it comes from, and a sentence with a figure that is not in its sources was removed. Not investment advice.